• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利：CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法，用中文像聊天一样搜索，搜遍4000万医学文献。AI智能推荐，让科研检索更轻松。

立即免费搜索

文件翻译

保留排版，准确专业，支持PDF/Word/PPT等文件格式，支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述，25分钟生成高质量综述，智能提取关键信息，辅助科研写作。

立即免费体验

Innovation in Neovascular Age-Related Macular Degeneration: Consideration of Brolucizumab, Abicipar, and the Port Delivery System.

作者信息

Wykoff Charles C, Hariprasad Seenu M, Zhou Brenda

出版信息

Ophthalmic Surg Lasers Imaging Retina. 2018 Dec 1;49(12):913-917. doi: 10.3928/23258160-20181203-01.

DOI:10.3928/23258160-20181203-01
PMID:30566697
Abstract
摘要

相似文献

1
Innovation in Neovascular Age-Related Macular Degeneration: Consideration of Brolucizumab, Abicipar, and the Port Delivery System.新生血管性年龄相关性黄斑变性的创新：布罗珠单抗、阿比西帕及端口递送系统的考量
Ophthalmic Surg Lasers Imaging Retina. 2018 Dec 1;49(12):913-917. doi: 10.3928/23258160-20181203-01.
2
Intravitreal bevacizumab in advanced-stage neovascular age-related macular degeneration with visual acuity lower than 20/200.玻璃体内注射贝伐单抗治疗视力低于20/200的晚期新生血管性年龄相关性黄斑变性
Arch Ophthalmol. 2012 Jul;130(7):934-5. doi: 10.1001/archophthalmol.2011.2617.
3
Incidence of Charles Bonnet syndrome after intravitreal bevacizumab injection in neovascular age-related macular degeneration.玻璃体内注射贝伐单抗治疗新生血管性年龄相关性黄斑变性后查尔斯·博内综合征的发生率
Acta Ophthalmol. 2012 Dec;90(8):e647-8. doi: 10.1111/j.1755-3768.2012.02421.x. Epub 2012 Apr 10.
4
Radiotherapy for anti-vascular endothelial growth factor injections for neovascular age-related macular degeneration.抗血管内皮生长因子注射治疗新生血管性年龄相关性黄斑变性的放射治疗
Lancet. 2024 Jul 6;404(10447):4-5. doi: 10.1016/S0140-6736(24)00915-2. Epub 2024 Jun 11.
5
Anti-vascular endothelial growth factor injection technique for recurrent exudative macular degeneration in a telescope-implanted eye.抗血管内皮生长因子注射技术用于人工晶状体植入眼复发性渗出性黄斑变性
Retin Cases Brief Rep. 2014 Fall;8(4):342-4. doi: 10.1097/ICB.0000000000000065.
6
Brolucizumab (Beovu) for age-related macular degeneration.用于年龄相关性黄斑变性的布罗珠单抗（Beovu）
Med Lett Drugs Ther. 2020 Feb 10;62(1591):23-24.
7
Infographic: Efficacy, durability, and safety of intravitreal faricimab up to every 16 weeks for neovascular age-related macular degeneration (TENAYA and LUCERNE).信息图：玻璃体内注射faricimab每16周一次治疗新生血管性年龄相关性黄斑变性的疗效、持久性和安全性（TENAYA和LUCERNE研究）
Eye (Lond). 2024 Aug;38(Suppl 2):53-54. doi: 10.1038/s41433-023-02867-4. Epub 2023 Dec 20.
8
Current state of therapeutic strategies with ranibizumab in neovascular age-related macular degeneration.
Curr Opin Ophthalmol. 2015 May;26(3):200-5. doi: 10.1097/ICU.0000000000000151.
9
Retreatment with anti-vascular endothelial growth factor therapy based on changes in visual acuity after initial stabilization of neovascular age-related macular degeneration: 3-year follow-up results.基于新生血管性年龄相关性黄斑变性初始稳定后视力变化的抗血管内皮生长因子治疗的再治疗：3 年随访结果。
Retina. 2012 Sep;32(8):1471-9. doi: 10.1097/IAE.0b013e318236e805.
10
Recalcitrant neovascular macular degeneration after anti-VEGF therapy: an ongoing challenge.
Ophthalmic Surg Lasers Imaging Retina. 2013 Mar-Apr;44(2):109. doi: 10.3928/23258160-20130313-01.

引用本文的文献

1
Current Management of Age-Related Macular Degeneration.年龄相关性黄斑变性的治疗现状。
Adv Exp Med Biol. 2021;1256:295-314. doi: 10.1007/978-3-030-66014-7_12.